Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus
Autore:
Rustemeijer, C; Schouten, JA; Voerman, HJ; Hensgens, HESJ; Donker, AJM; Heine, RJ;
Indirizzi:
Ziekenhuis Amstelveen, Dept Internal Med, NL-1180 AH Amstelveen, Netherlands Ziekenhuis Amstelveen Amstelveen Netherlands NL-1180 AH een, Netherlands Free Univ Amsterdam Hosp, Dept Internal Med, Amsterdam, Netherlands Free Univ Amsterdam Hosp Amsterdam Netherlands , Amsterdam, Netherlands Ziekenhuis Amstelveen, Dept Biochem, Amstelveen, Netherlands Ziekenhuis Amstelveen Amstelveen Netherlands m, Amstelveen, Netherlands
Titolo Testata:
DIABETES-METABOLISM RESEARCH AND REVIEWS
fascicolo: 2, volume: 16, anno: 2000,
pagine: 82 - 87
SICI:
1520-7552(200003/04)16:2<82:PCTBIT>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; LIPOPROTEIN PARTICLE-SIZE; MIDDLE-AGED MEN; RISK-FACTORS; CARDIOVASCULAR MORTALITY; MYOCARDIAL-INFARCTION; INTERVENTION TRIAL; CHOLESTEROL LEVELS; GLUCOSE CONTROL; ARTERY DISEASE;
Keywords:
pravastatin; bezafibrate; Type 2 diabetes mellitus (DM); lipids; lipoprotein composition;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Rustemeijer, C Ziekenhuis Amstelveen, Dept Internal Med, POB 328, NL-1180 AH Amstelveen, Netherlands Ziekenhuis Amstelveen POB 328 Amstelveen Netherlands NL-1180 AH
Citazione:
C. Rustemeijer et al., "Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus", DIABET M R, 16(2), 2000, pp. 82-87

Abstract

Background Both HMG-CoA reductase inhibitors and fibric acid derivates areused for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg bezafibrate, a fibric acid derivate, on serum lipids, lipoproteins and lipoprotein composition in 45 (22men and 23 women) dyslipidemic, insulin-treated Type 2 diabetes patients. Method The study used a double-blind, cross-over design. Results Pravastatin treatment was more effective in reducing total cholesterol, LDL-cholesterol, LDL-triglycerides, LDL-ApoB and LDL/HDL-cholesterol ratio (all p<0.001 between groups) and total/HDL-cholesterol and ApoA1/LDL-ApoB ratios (both p<0.01) and always induced a decrease in LDL-cholesterol concentrations and LDL/HDL-cholesterol ratio irrespective of baseline triglyceride concentration. Bezafibrate was more effective in increasing HDL-cholesterol (p<0.01 between groups), ApoA1 lipoprotein and decreasing triglycerides (both p<0.001 between groups) but induced an increase in LDL-cholesterol concentration particularly in patients with baseline triglyceride concentrations exceeding 2.0 mmol/l. With bezafibrate treatment the LDL-cholesterol/LDL-ApoB ratio showed a tendency to rise, suggesting a change in the LDL particle composition to a less small and dense form, while pravastatin treatment induced a decrease in this ratio suggesting a change in the LDL particle to a more dense form. With pravastatin treatment a small rise in HbA(1c) was observed. Conclusion Pravastatin treatment is superior in lowering cholesterol-enriched lipoprotein subpopulations and improving cardiovascular risk factors. Bezafibrate is more effective in raising HDL-cholesterol and alters LDL particle composition to a more favorable form. Copyright (C) 2000 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 21:58:57